Launch of novel stent technology with 10-year safety and efficacy data adds further momentum to the company's global growth journey
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Bionova Scientific’s process development capabilities are particularly highly regarded in the industry, and it has a rich track record regarding complex next-generation antibody drugs, which are typically challenging to manufacture
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using Comera's innovative proprietary SQore formulation platform
The facility will support clinical development by securing supply that will address the critical demand in the gene therapy and vaccine markets
This partnership allows both companies to become first movers to bridge an inevitable gap with the largest organizations in the pharmaceutical, nutraceutical, cosmetic, and veterinary sectors
The US $600 million acquisition will see Juniper Biologics offer the world's first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa
Shoreline has developed a proprietary methodology to create differentiated iNK cells for large-scale, "off-the-shelf" production
The peptide-based vaccine induces a t cell-dependent response
Nuvaxovid is the first protein-based Covid-19 vaccine authorized for use in Switzerland
Subscribe To Our Newsletter & Stay Updated
